Previous 10 | Next 10 |
2024-01-03 12:20:37 ET DENVER, Colo., Jan. 3, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Sidus Space Inc (NASDAQ: SIDU), ABVC Biopharma Inc (NASDAQ: ABVC), Dyne Therapeutics Inc (NASDAQ: DYN),...
2024-01-03 10:06:54 ET DENVER, Colo., Jan. 3, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ABVC Biopharma Inc (NASDAQ: ABVC), Dyne Therapeutics Inc (NASDAQ: DYN), Sidus Space Inc (NASDAQ: SIDU), Neximm...
2024-01-03 10:00:01 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...
2024-01-03 07:15:08 ET More on Dyne Therapeutics Seeking Alpha’s Quant Rating on Dyne Therapeutics Historical earnings data for Dyne Therapeutics Financial information for Dyne Therapeutics For further details see: Dyne surges on positive Phase 1/2...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gen...
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report initial clinic...
2023-12-03 20:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to ...
Dyne Therapeutics Inc. (DYN) is expected to report $-0.86 for Q3 2023
2023-10-30 07:34:39 ET More on Dyne Therapeutics Dyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early Stages Dyne Therapeutics gets FDA orphan drug status for DM1 drug Seeking Alpha’s Quant Rating on Dyne Therapeutics Historical earnings ...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advanc...
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten pu...
2024-05-21 08:00:14 ET Keay Nakae from Chardan Capital issued a price target of $42.00 for DYN on 2024-05-21 07:09:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.38. The overall price target consensus is at $34.00...